✦ LIBER ✦

P-217 K-ras mutations in serum DNA of early non-small-cell lung cancer (NSCLC) patients (p): A genetic analysis of an ongoing randomized neoadjuvant/adjuvant paclitaxel/carboplatin trial

✍ Scribed by Manzano, Jose Luis; De Aguirre, Itziar; Botia, Monica; Ramirez, Jose Luis; Massuti, Bartomeu; Queralt, Cristina; Sanchez, Jose Miguel; Almenarez, Jose; Taron, Miguel; Rosell, Rafael

Book ID: 118571918
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 189 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92186-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-215 Analysis of xeroderma pigmentosum

P-215 Analysis of xeroderma pigmentosum complementation group D (XPD) in the NATCH trial: a neoadjuvant/adjuvant paclitaxel/carboplatin trial in early non-small-cell lung cancer (NSCLC)

✍ Felip, Enriqueta; Massuti, Bartomeu; de Aguirre, Itziar; Alonso, Guillermo; Maes 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 369 KB

O-086a Randomized phase II/III trial of

O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599

✍ Sandler, A.B.; Gray, R.; Brahmer, J.; Dowlati, A.; Schiller, J.H.; Perry, M.C.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 151 KB

OP78 EGFR mutations based on circulating

OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)

✍ N. Yamamoto; Y. Ichinose; Y. Nishiwaki; Y. Ohe; K. Nishio; H. Jiang; E. Duffield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 40 KB